

# Gavin J Churchyard

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4439853/publications.pdf>

Version: 2024-02-01

193  
papers

12,603  
citations

36691

53  
h-index

32181

105  
g-index

198  
all docs

198  
docs citations

198  
times ranked

13433  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Diarylquinoline TMC207 for Multidrug-Resistant Tuberculosis. <i>New England Journal of Medicine</i> , 2009, 360, 2397-2405.	13.9	763
2	The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study. <i>European Respiratory Journal</i> , 2013, 42, 1604-1613.	3.1	683
3	The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. <i>Lancet Respiratory Medicine</i> , 2017, 5, 291-360.	5.2	459
4	HIV infection and tuberculosis in South Africa: an urgent need to escalate the public health response. <i>Lancet</i> , 2009, 374, 921-933.	6.3	414
5	High-Dose Rifapentine with Moxifloxacin for Pulmonary Tuberculosis. <i>New England Journal of Medicine</i> , 2014, 371, 1599-1608.	13.9	383
6	Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial. <i>Lancet</i> , 2014, 383, 424-435.	6.3	379
7	Safety and efficacy of the HVTN 503/Phambili Study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study. <i>Lancet Infectious Diseases</i> , 2011, 11, 507-515.	4.6	330
8	Development of a Standardized Screening Rule for Tuberculosis in People Living with HIV in Resource-Constrained Settings: Individual Participant Data Meta-analysis of Observational Studies. <i>PLoS Medicine</i> , 2011, 8, e1000391.	3.9	328
9	High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial. <i>Lancet Infectious Diseases</i> , 2017, 17, 39-49.	4.6	294
10	Comparison of two active case-finding strategies for community-based diagnosis of symptomatic smear-positive tuberculosis and control of infectious tuberculosis in Harare, Zimbabwe (DETECTB): a cluster-randomised trial. <i>Lancet</i> , 2010, 376, 1244-1253.	6.3	276
11	Building a tuberculosis-free world: The Lancet Commission on tuberculosis. <i>Lancet</i> , 2019, 393, 1331-1384.	6.3	257
12	Immunological mechanisms of human resistance to persistent <i>Mycobacterium tuberculosis</i> infection. <i>Nature Reviews Immunology</i> , 2018, 18, 575-589.	10.6	241
13	Advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers. <i>Lancet Infectious Diseases</i> , 2016, 16, e34-e46.	4.6	223
14	Achieving the health Millennium Development Goals for South Africa: challenges and priorities. <i>Lancet</i> , 2009, 374, 1023-1031.	6.3	214
15	Effect on mortality of point-of-care, urine-based lipoarabinomannan testing to guide tuberculosis treatment initiation in HIV-positive hospital inpatients: a pragmatic, parallel-group, multicountry, open-label, randomised controlled trial. <i>Lancet</i> , 2016, 387, 1187-1197.	6.3	211
16	Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa. <i>Aids</i> , 2008, 22, 1971-1977.	1.0	195
17	A Trial of Mass Isoniazid Preventive Therapy for Tuberculosis Control. <i>New England Journal of Medicine</i> , 2014, 370, 301-310.	13.9	194
18	What We Know About Tuberculosis Transmission: An Overview. <i>Journal of Infectious Diseases</i> , 2017, 216, S629-S635.	1.9	193

#	ARTICLE	IF	CITATIONS
19	Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodies. <i>Science</i> , 2015, 349, aab1253.	6.0	191
20	Xpert MTB/RIF versus sputum microscopy as the initial diagnostic test for tuberculosis: a cluster-randomised trial embedded in South African roll-out of Xpert MTB/RIF. <i>The Lancet Global Health</i> , 2015, 3, e450-e457.	2.9	179
21	Morbidity and Mortality in South African Gold Miners: Impact of Untreated Disease Due to Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2002, 34, 1251-1258.	2.9	169
22	Antiretrovirals and isoniazid preventive therapy in the prevention of HIV-associated tuberculosis in settings with limited health-care resources. <i>Lancet Infectious Diseases</i> , The, 2010, 10, 489-498.	4.6	165
23	Human Immunodeficiency Virus and the Prevalence of Undiagnosed Tuberculosis in African Gold Miners. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2004, 170, 673-679.	2.5	154
24	HIV infection and silicosis: the impact of two potent risk factors on the incidence of mycobacterial disease in South African miners. <i>Aids</i> , 2000, 14, 2759-2768.	1.0	153
25	Epidemiology of HIV-associated tuberculosis. <i>Current Opinion in HIV and AIDS</i> , 2009, 4, 325-333.	1.5	145
26	Feasibility of achieving the 2025 WHO global tuberculosis targets in South Africa, China, and India: a combined analysis of 11 mathematical models. <i>The Lancet Global Health</i> , 2016, 4, e806-e815.	2.9	138
27	Tuberculosis Vaccines and Prevention of Infection. <i>Microbiology and Molecular Biology Reviews</i> , 2014, 78, 650-671.	2.9	133
28	A Phase IIA Randomized Clinical Trial of a Multiclade HIV-1 DNA Prime Followed by a Multiclade rAd5 HIV-1 Vaccine Boost in Healthy Adults (HVTN204). <i>PLoS ONE</i> , 2011, 6, e21225.	1.1	131
29	"That is why I stopped the ART": Patients' & providers' perspectives on barriers to and enablers of HIV treatment adherence in a South African workplace programme. <i>BMC Public Health</i> , 2008, 8, 63.	1.2	122
30	The economic burden of TB diagnosis and treatment in South Africa. <i>Social Science and Medicine</i> , 2015, 130, 42-50.	1.8	122
31	Hepatitis B Virus Infection and Response to Antiretroviral Therapy (ART) in a South African ART Program. <i>Clinical Infectious Diseases</i> , 2008, 47, 1479-1485.	2.9	119
32	Scale-up of services and research priorities for diagnosis, management, and control of tuberculosis: a call to action. <i>Lancet</i> , The, 2010, 375, 2179-2191.	6.3	114
33	Towards host-directed therapies for tuberculosis. <i>Nature Reviews Drug Discovery</i> , 2015, 14, 511-512.	21.5	110
34	Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study. <i>Lancet Infectious Diseases</i> , The, 2014, 14, 388-396.	4.6	108
35	Viremia, Resuppression, and Time to Resistance in Human Immunodeficiency Virus (HIV) Subtype C during First-Line Antiretroviral Therapy in South Africa. <i>Clinical Infectious Diseases</i> , 2009, 49, 1928-1935.	2.9	107
36	Epidemiology of Tuberculosis in a High HIV Prevalence Population Provided with Enhanced Diagnosis of Symptomatic Disease. <i>PLoS Medicine</i> , 2007, 4, e22.	3.9	106

#	ARTICLE	IF	CITATIONS
37	Detection and Quantification of Differentially Culturable Tubercle Bacteria in Sputum from Patients with Tuberculosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 194, 1532-1540.	2.5	105
38	Safety, Tolerability, and Immunogenicity of the Novel Antituberculous Vaccine RUTI: Randomized, Placebo-Controlled Phase II Clinical Trial in Patients with Latent Tuberculosis Infection. <i>PLoS ONE</i> , 2014, 9, e89612.	1.1	101
39	The Lancet Respiratory Medicine Commission: 2019 update: epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant and incurable tuberculosis. <i>Lancet Respiratory Medicine</i> , 2019, 7, 820-826.	5.2	92
40	Biomarker-guided tuberculosis preventive therapy (CORTIS): a randomised controlled trial. <i>Lancet Infectious Diseases</i> , 2021, 21, 354-365.	4.6	84
41	The Potential for Treatment Shortening With Higher Rifampicin Doses: Relating Drug Exposure to Treatment Response in Patients With Pulmonary Tuberculosis. <i>Clinical Infectious Diseases</i> , 2018, 67, 34-41.	2.9	80
42	Using Top-down and Bottom-up Costing Approaches in LMICs: The Case for Using Both to Assess the Incremental Costs of New Technologies at Scale. <i>Health Economics (United Kingdom)</i> , 2016, 25, 53-66.	0.8	74
43	Barriers to implementation of isoniazid preventive therapy in HIV clinics: a qualitative study. <i>Aids</i> , 2010, 24, S45-S48.	1.0	72
44	Tuberculosis Preventive Therapy in the Era of HIV Infection: Overview and Research Priorities. <i>Journal of Infectious Diseases</i> , 2007, 196, S52-S62.	1.9	70
45	Provider-initiated symptom screening for tuberculosis in Zimbabwe: diagnostic value and the effect of HIV status. <i>Bulletin of the World Health Organization</i> , 2010, 88, 13-21.	1.5	69
46	Cost-effectiveness and resource implications of aggressive action on tuberculosis in China, India, and South Africa: a combined analysis of nine models. <i>The Lancet Global Health</i> , 2016, 4, e816-e826.	2.9	69
47	Tuberculosis Infectiousness and Host Susceptibility. <i>Journal of Infectious Diseases</i> , 2017, 216, S636-S643.	1.9	65
48	The burden of silicosis, pulmonary tuberculosis and COPD among former Basotho goldminers. <i>American Journal of Industrial Medicine</i> , 2008, 51, 640-647.	1.0	64
49	Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective, open-label, phase 2, randomised controlled trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 897-908.	5.2	64
50	High Tuberculosis Prevalence in a South African Prison: The Need for Routine Tuberculosis Screening. <i>PLoS ONE</i> , 2014, 9, e87262.	1.1	61
51	Comparison of Tenofovir, Zidovudine, or Stavudine as Part of First-Line Antiretroviral Therapy in a Resource-Limited-Setting: A Cohort Study. <i>PLoS ONE</i> , 2013, 8, e64459.	1.1	59
52	The relationship between <i>Mycobacterium tuberculosis</i> MGIT time to positivity and cfu in sputum samples demonstrates changing bacterial phenotypes potentially reflecting the impact of chemotherapy on critical sub-populations. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 448-455.	1.3	58
53	Differential Specificity and Immunogenicity of Adenovirus Type 5 Neutralizing Antibodies Elicited by Natural Infection or Immunization. <i>Journal of Virology</i> , 2010, 84, 630-638.	1.5	57
54	Tuberculosis outcomes and drug susceptibility in individuals exposed to isoniazid preventive therapy in a high HIV prevalence setting. <i>Aids</i> , 2010, 24, 1051-1055.	1.0	55

#	ARTICLE	IF	CITATIONS
55	Advances in Immunotherapy for Tuberculosis Treatment. <i>Clinics in Chest Medicine</i> , 2009, 30, 769-782.	0.8	54
56	Cost-effectiveness of Xpert MTB/RIF for tuberculosis diagnosis in South Africa: a real-world cost analysis and economic evaluation. <i>The Lancet Global Health</i> , 2017, 5, e710-e719.	2.9	53
57	Effect of Xpert MTB/RIF on clinical outcomes in routine care settings: individual patient data meta-analysis. <i>The Lancet Global Health</i> , 2019, 7, e191-e199.	2.9	53
58	Recurrent Tuberculosis: Relapse, Reinfection, and HIV. <i>Journal of Infectious Diseases</i> , 2010, 201, 653-655.	1.9	52
59	Safety and Immunogenicity of H1/IC31A®, an Adjuvanted TB Subunit Vaccine, in HIV-Infected Adults with CD4+ Lymphocyte Counts Greater than 350 cells/mm <sup>3</sup> : A Phase II, Multi-Centre, Double-Blind, Randomized, Placebo-Controlled Trial. <i>PLoS ONE</i> , 2014, 9, e114602.	1.1	52
60	Performance Characteristics of the Cepheid Xpert MTB/RIF Test in a Tuberculosis Prevalence Survey. <i>PLoS ONE</i> , 2012, 7, e43307.	1.1	51
61	HIV Infection Does Not Affect Active Case Finding of Tuberculosis in South African Gold Miners. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009, 180, 1271-1278.	2.5	48
62	Comparison of laboratory costs of rapid molecular tests and conventional diagnostics for detection of tuberculosis and drug-resistant tuberculosis in South Africa. <i>BMC Infectious Diseases</i> , 2013, 13, 352.	1.3	47
63	Viral Suppression Following Switch to Second-line Antiretroviral Therapy: Associations With Nucleoside Reverse Transcriptase Inhibitor Resistance and Subtherapeutic Drug Concentrations Prior to Switch. <i>Journal of Infectious Diseases</i> , 2014, 209, 711-720.	1.9	47
64	Four Models of HIV Counseling and Testing: Utilization and Test Results in South Africa. <i>PLoS ONE</i> , 2014, 9, e102267.	1.1	46
65	TB sequel: incidence, pathogenesis and risk factors of long-term medical and social sequelae of pulmonary TB "a study protocol. <i>BMC Pulmonary Medicine</i> , 2019, 19, 4.	0.8	45
66	Outcomes Following Virological Failure and Predictors of Switching to Second-line Antiretroviral Therapy in a South African Treatment Program. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 61, 370-380.	0.9	43
67	Cost-effectiveness of Preventive Therapy for Tuberculosis With Isoniazid and Rifapentine Versus Isoniazid Alone in High-Burden Settings. <i>Clinical Infectious Diseases</i> , 2018, 67, 1072-1078.	2.9	43
68	Adverse events with isoniazid preventive therapy: experience from a large trial. <i>Aids</i> , 2010, 24, S29-S36.	1.0	42
69	Autopsy Prevalence of Tuberculosis and Other Potentially Treatable Infections among Adults with Advanced HIV Enrolled in Out-Patient Care in South Africa. <i>PLoS ONE</i> , 2016, 11, e0166158.	1.1	42
70	Incidence of tuberculosis and HIV and progression of silicosis and lung function impairment among former basotho gold miners. <i>American Journal of Industrial Medicine</i> , 2009, 52, 901-908.	1.0	41
71	Once-weekly rifapentine and isoniazid for tuberculosis prevention in patients with HIV taking dolutegravir-based antiretroviral therapy: a phase 1/2 trial. <i>Lancet HIV</i> , 2020, 7, e401-e409.	2.1	41
72	Missed Opportunities for TB Investigation in Primary Care Clinics in South Africa: Experience from the XTEND Trial. <i>PLoS ONE</i> , 2015, 10, e0138149.	1.1	41

#	ARTICLE	IF	CITATIONS
73	Risk factors for poor virological outcome at 12 months in a workplace-based antiretroviral therapy programme in South Africa: A cohort study. <i>BMC Infectious Diseases</i> , 2008, 8, 93.	1.3	40
74	Cytomegalovirus Viremia as a Risk Factor for Mortality Prior to Antiretroviral Therapy among HIV-Infected Gold Miners in South Africa. <i>PLoS ONE</i> , 2011, 6, e25571.	1.1	40
75	Undiagnosed Tuberculosis Among HIV Clinic Attendees. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2012, 60, e22-e28.	0.9	39
76	Diagnosing Latent Tuberculosis in High-Risk Individuals: Rising to the Challenge in High-Burden Areas. <i>Journal of Infectious Diseases</i> , 2011, 204, S1168-S1178.	1.9	38
77	Tuberculosis Control in South African Gold Mines: Mathematical Modeling of a Trial of Community-Wide Isoniazid Preventive Therapy. <i>American Journal of Epidemiology</i> , 2015, 181, 619-632.	1.6	38
78	Changing Predictors of Mortality Over Time From cART Start. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2011, 58, 269-276.	0.9	37
79	Genotype MTBDRplus for Direct Detection of Mycobacterium tuberculosis and Drug Resistance in Strains from Gold Miners in South Africa. <i>Journal of Clinical Microbiology</i> , 2012, 50, 1189-1194.	1.8	35
80	“Proof-Of-Concept” Evaluation of an Automated Sputum Smear Microscopy System for Tuberculosis Diagnosis. <i>PLoS ONE</i> , 2012, 7, e50173.	1.1	35
81	The safety and immunogenicity of an adenovirus type 35-vectored TB vaccine in HIV-infected, BCG-vaccinated adults with CD4+ T cell counts $\geq 350$ cells/mm <sup>3</sup> . <i>Vaccine</i> , 2015, 33, 1890-1896.	1.7	35
82	The patient costs of care for those with TB and HIV: a cross-sectional study from South Africa. <i>Health Policy and Planning</i> , 2017, 32, iv48-iv56.	1.0	35
83	Association of isoniazid preventive therapy with lower early mortality in individuals on antiretroviral therapy in a workplace programme. <i>Aids</i> , 2010, 24, S5-S13.	1.0	34
84	Validation of a host blood transcriptomic biomarker for pulmonary tuberculosis in people living with HIV: a prospective diagnostic and prognostic accuracy study. <i>The Lancet Global Health</i> , 2021, 9, e841-e853.	2.9	34
85	Trends in silicosis prevalence and the healthy worker effect among gold miners in South Africa: a prevalence study with follow up of employment status. <i>BMC Public Health</i> , 2015, 15, 1258.	1.2	33
86	Low haemoglobin predicts early mortality among adults starting antiretroviral therapy in an HIV care programme in South Africa: a cohort study. <i>BMC Public Health</i> , 2010, 10, 433.	1.2	32
87	Algorithm-guided empirical tuberculosis treatment for people with advanced HIV (TB Fast Track): an open-label, cluster-randomised trial. <i>Lancet HIV</i> , 2020, 7, e27-e37.	2.1	32
88	Reducing mortality with cotrimoxazole preventive therapy at initiation of antiretroviral therapy in South Africa. <i>Aids</i> , 2010, 24, 1709-1716.	1.0	31
89	Thibela TB: Design and methods of a cluster randomised trial of the effect of community-wide isoniazid preventive therapy on tuberculosis amongst gold miners in South Africa. <i>Contemporary Clinical Trials</i> , 2011, 32, 382-392.	0.8	31
90	Controlling latent TB tuberculosis infection in high-burden countries: A neglected strategy to end TB. <i>PLoS Medicine</i> , 2019, 16, e1002787.	3.9	31

#	ARTICLE	IF	CITATIONS
91	Incidence of HIV-Associated Tuberculosis among Individuals Taking Combination Antiretroviral Therapy: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2014, 9, e111209.	1.1	31
92	Contrasting predictors of poor antiretroviral therapy outcomes in two South African HIV programmes: a cohort study. <i>BMC Public Health</i> , 2010, 10, 430.	1.2	30
93	Diagnostic Accuracy of a Urine Lipoarabinomannan Enzyme-Linked Immunosorbent Assay for Screening Ambulatory HIV-Infected Persons for Tuberculosis. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2011, 58, 219-223.	0.9	30
94	Mortality Associated With Delays Between Clinic Entry and ART Initiation in Resource-Limited Settings. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2013, 63, 105-111.	0.9	30
95	Continued Follow-Up of Phambili Phase 2b Randomized HIV-1 Vaccine Trial Participants Supports Increased HIV-1 Acquisition among Vaccinated Men. <i>PLoS ONE</i> , 2015, 10, e0137666.	1.1	30
96	Second-Line Antiretroviral Therapy in a Workplace and Community-Based Treatment Programme in South Africa: Determinants of Virological Outcome. <i>PLoS ONE</i> , 2012, 7, e36997.	1.1	29
97	Considerations for biomarker-targeted intervention strategies for tuberculosis disease prevention. <i>Tuberculosis</i> , 2018, 109, 61-68.	0.8	28
98	A clinical scoring system to prioritise investigation for tuberculosis among adults attending HIV clinics in South Africa. <i>PLoS ONE</i> , 2017, 12, e0181519.	1.1	28
99	Tuberculosis screening among ambulatory people living with HIV: a systematic review and individual participant data meta-analysis. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 507-518.	4.6	28
100	An evaluation framework for new tests that predict progression from tuberculosis infection to clinical disease. <i>European Respiratory Journal</i> , 2018, 52, 1800946.	3.1	27
101	Prediction of anti-tuberculosis treatment duration based on a 22-gene transcriptomic model. <i>European Respiratory Journal</i> , 2021, 58, 2003492.	3.1	27
102	Contrasting Reasons for Discontinuation of Antiretroviral Therapy in Workplace and Public-Sector HIV Programs in South Africa. <i>AIDS Patient Care and STDs</i> , 2011, 25, 53-59.	1.1	26
103	Distinct susceptibility of HIV vaccine vector-induced CD4 T cells to HIV infection. <i>PLoS Pathogens</i> , 2018, 14, e1006888.	2.1	26
104	Performance of a Novel Algorithm Using Automated Digital Microscopy for Diagnosing Tuberculosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 191, 1443-1449.	2.5	25
105	Target regimen profiles for treatment of tuberculosis: a WHO document. <i>European Respiratory Journal</i> , 2017, 49, 1602352.	3.1	25
106	Measuring mortality due to HIV-associated tuberculosis among adults in South Africa: Comparing verbal autopsy, minimally-invasive autopsy, and research data. <i>PLoS ONE</i> , 2017, 12, e0174097.	1.1	24
107	Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials. <i>PLoS ONE</i> , 2015, 10, e0136626.	1.1	23
108	Symptom and chest radiographic screening for infectious tuberculosis prior to starting isoniazid preventive therapy: yield and proportion missed at screening. <i>Aids</i> , 2010, 24, S19-S27.	1.0	22

#	ARTICLE	IF	CITATIONS
109	Twelve-monthly versus six-monthly radiological screening for active case-finding of tuberculosis: a randomised controlled trial. <i>Thorax</i> , 2011, 66, 134-139.	2.7	22
110	Using mHealth to improve tuberculosis case identification and treatment initiation in South Africa: Results from a pilot study. <i>PLoS ONE</i> , 2018, 13, e0199687.	1.1	22
111	Priority-Setting for Novel Drug Regimens to Treat Tuberculosis: An Epidemiologic Model. <i>PLoS Medicine</i> , 2017, 14, e1002202.	3.9	20
112	Resistance to Tenofovir-Based Regimens during Treatment Failure of Subtype C HIV-1 in South Africa. <i>Antiviral Therapy</i> , 2013, 18, 915-920.	0.6	19
113	Guidance for Studies Evaluating the Accuracy of Sputum-Based Tests to Diagnose Tuberculosis. <i>Journal of Infectious Diseases</i> , 2019, 220, S99-S107.	1.9	19
114	Aspiring to Zero Tuberculosis Deaths among Southern Africa's Miners: Is There a Way Forward?. <i>International Journal of Health Services</i> , 2013, 43, 651-664.	1.2	18
115	Tuberculosis preventive therapy: An underutilised strategy to reduce individual risk of TB and contribute to TB control. <i>South African Medical Journal</i> , 2014, 104, 339.	0.2	18
116	The timing of tuberculosis after isoniazid preventive therapy among gold miners in South Africa: a prospective cohort study. <i>BMC Medicine</i> , 2016, 14, 45.	2.3	18
117	Predictors of silicosis and variation in prevalence across mines among employed gold miners in South Africa. <i>BMC Public Health</i> , 2020, 20, 829.	1.2	18
118	Tuberculosis preventive therapy for people living with HIV: A systematic review and network meta-analysis. <i>PLoS Medicine</i> , 2021, 18, e1003738.	3.9	18
119	What Is Thwarting Tuberculosis Prevention in High-Burden Settings?. <i>New England Journal of Medicine</i> , 2011, 365, 79-81.	13.9	17
120	Tuberculosis Prevention in South Africa. <i>PLoS ONE</i> , 2015, 10, e0122514.	1.1	17
121	Strategies to Accelerate HIV Care and Antiretroviral Therapy Initiation After HIV Diagnosis: A Randomized Trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 75, 540-547.	0.9	17
122	Research Roadmap for Tuberculosis Transmission Science: Where Do We Go From Here and How Will We Know When We're There?. <i>Journal of Infectious Diseases</i> , 2017, 216, S662-S668.	1.9	17
123	Diagnostic Accuracy of Lateral Flow Urine LAM Assay for TB Screening of Adults with Advanced Immunosuppression Attending Routine HIV Care in South Africa. <i>PLoS ONE</i> , 2016, 11, e0156866.	1.1	17
124	Pan-tuberculosis regimens: an argument for. <i>Lancet Respiratory Medicine</i> , 2018, 6, 239-240.	5.2	16
125	Sequential Immunization with gp140 Boosts Immune Responses Primed by Modified Vaccinia Ankara or DNA in HIV-Uninfected South African Participants. <i>PLoS ONE</i> , 2016, 11, e0161753.	1.1	16
126	A novel HIV treatment model using private practitioners in South Africa. <i>Sexually Transmitted Infections</i> , 2012, 88, 136-140.	0.8	15



#	ARTICLE	IF	CITATIONS
127	Heat Inactivation Renders Sputum Safe and Preserves <i>Mycobacterium tuberculosis</i> RNA for Downstream Molecular Tests. <i>Journal of Clinical Microbiology</i> , 2019, 57, .	1.8	15
128	The Impact of Company-Level ART Provision to a Mining Workforce in South Africa: A Cost-Benefit Analysis. <i>PLoS Medicine</i> , 2015, 12, e1001869.	3.9	15
129	Prospective multicentre head-to-head validation of host blood transcriptomic biomarkers for pulmonary tuberculosis by real-time PCR. <i>Communications Medicine</i> , 2022, 2, .	1.9	15
130	Expanding HIV care in Africa: making men matter in Johannesburg. <i>Lancet</i> , The, 2009, 374, 1329.	6.3	14
131	Clinical Relevance of Nontuberculous Mycobacteria Isolated from Sputum in a Gold Mining Workforce in South Africa: An Observational, Clinical Study. <i>BioMed Research International</i> , 2015, 2015, 1-10.	0.9	14
132	Molecular Epidemiology of <i>Mycobacterium tuberculosis</i> among South African Gold Miners. <i>Annals of the American Thoracic Society</i> , 2015, 12, 12-20.	1.5	14
133	Outcomes of on-site antiretroviral therapy provision in a South African correctional facility. <i>International Journal of STD and AIDS</i> , 2016, 27, 1153-1161.	0.5	14
134	Household HIV Testing Uptake among Contacts of TB Patients in South Africa. <i>PLoS ONE</i> , 2016, 11, e0155688.	1.1	14
135	Team up against TB™: promoting involvement in Thibela TB, a trial of community-wide tuberculosis preventive therapy. <i>Aids</i> , 2010, 24, S37-S44.	1.0	13
136	A Trial of Mass Isoniazid Preventive Therapy for Tuberculosis Control. <i>New England Journal of Medicine</i> , 2014, 370, 1661-1663.	13.9	13
137	Implementing a Large-Scale Systematic Tuberculosis Screening Program in Correctional Facilities in South Africa. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofu121.	0.4	13
138	Evaluation of a point-of-care tuberculosis test-and-treat algorithm on early mortality in people with HIV accessing antiretroviral therapy (TB Fast Track study): study protocol for a cluster randomised controlled trial. <i>Trials</i> , 2015, 16, 125.	0.7	13
139	Impact of Targeted Tuberculosis Vaccination Among a Mining Population in South Africa: A Model-Based Study. <i>American Journal of Epidemiology</i> , 2017, 186, 1362-1369.	1.6	13
140	Protein binding of rifampicin is not saturated when using high-dose rifampicin. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 986-990.	1.3	13
141	Isoniazid preventive therapy for HIV-infected people: evidence to support implementation. <i>Aids</i> , 2010, 24, S1-S3.	1.0	12
142	Molecular characterisation of clinical and environmental isolates of <i>Mycobacterium kansasii</i> isolates from South African gold mines. <i>Journal of Water and Health</i> , 2015, 13, 190-202.	1.1	12
143	Empiric tuberculosis treatment in South African primary health care facilities - for whom, where, when and why: Implications for the development of tuberculosis diagnostic tests. <i>PLoS ONE</i> , 2018, 13, e0191608.	1.1	12
144	Plasma host protein biomarkers correlating with increasing <i>Mycobacterium tuberculosis</i> infection activity prior to tuberculosis diagnosis in people living with HIV. <i>EBioMedicine</i> , 2022, 75, 103787.	2.7	12

#	ARTICLE	IF	CITATIONS
145	Small contribution of gold mines to the ongoing tuberculosis epidemic in South Africa: a modeling-based study. <i>BMC Medicine</i> , 2018, 16, 52.	2.3	11
146	Neutrophils Contribute to Severity of Tuberculosis Pathology and Recovery From Lung Damage Pre- and Posttreatment. <i>Clinical Infectious Diseases</i> , 2022, 74, 1757-1766.	2.9	11
147	Durable <scp>HIV RNA</scp> resuppression after virologic failure while remaining on a first-line regimen: a cohort study. <i>Tropical Medicine and International Health</i> , 2014, 19, 236-239.	1.0	10
148	The Diagnostic Accuracy of Urine Lipoarabinomannan Test for Tuberculosis Screening in a South African Correctional Facility. <i>PLoS ONE</i> , 2015, 10, e0127956.	1.1	10
149	Antiviral Innate Immune Activation in HIV-Infected Adults Negatively Affects H1/IC31-Induced Vaccine-Specific Memory CD4 <sup>+</sup> T Cells. <i>Vaccine Journal</i> , 2015, 22, 688-696.	3.2	10
150	Verbal autopsy-assigned causes of death among adults being investigated for TB in South Africa. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2016, 110, 510-516.	0.7	10
151	Monitoring Anti-tuberculosis Treatment Response Using Analysis of Whole Blood Mycobacterium tuberculosis Specific T Cell Activation and Functional Markers. <i>Frontiers in Immunology</i> , 2020, 11, 572620.	2.2	10
152	Impact of vaccine type on HIV-1 vaccine elicited antibody durability and B cell gene signature. <i>Scientific Reports</i> , 2020, 10, 13031.	1.6	10
153	Clinic-level factors influencing patient outcomes on antiretroviral therapy in primary health clinics in South Africa. <i>Aids</i> , 2016, 30, 1099-1109.	1.0	9
154	Application of provincial data in mathematical modelling to inform sub-national tuberculosis program decision-making in South Africa. <i>PLoS ONE</i> , 2019, 14, e0209320.	1.1	9
155	Patient costs incurred by people living with HIV/AIDS prior to ART initiation in primary healthcare facilities in Gauteng, South Africa. <i>PLoS ONE</i> , 2019, 14, e0210622.	1.1	9
156	Predictors of HVTN 503 MRK-AD5 HIV-1 gag/pol/nef Vaccine Induced Immune Responses. <i>PLoS ONE</i> , 2014, 9, e103446.	1.1	9
157	Cost-Effectiveness of Automated Digital Microscopy for Diagnosis of Active Tuberculosis. <i>PLoS ONE</i> , 2016, 11, e0157554.	1.1	9
158	HIV suppression with stavudine 30 mg versus 40 mg in adults over 60 kg on antiretroviral therapy in South Africa. <i>Aids</i> , 2009, 23, 1784-1786.	1.0	8
159	Why have trials of isoniazid preventive therapy among people with HIV infection not demonstrated an effect on mortality?. <i>Aids</i> , 2010, 24, S15-S18.	1.0	8
160	Pregnancy Incidence and Correlates during the HVTN 503 Phambili HIV Vaccine Trial Conducted among South African Women. <i>PLoS ONE</i> , 2012, 7, e31387.	1.1	8
161	The incidence of tuberculosis among hiv-positive individuals with high CD4 counts: implications for policy. <i>BMC Infectious Diseases</i> , 2016, 16, 266.	1.3	8
162	A stratified approach to tuberculosis treatment. <i>Nature Medicine</i> , 2018, 24, 1639-1641.	15.2	8

#	ARTICLE	IF	CITATIONS
163	A Short Regimen for Rifampin-Resistant Tuberculosis. <i>New England Journal of Medicine</i> , 2019, 380, 1279-1280.	13.9	8
164	Monocyte Transcriptional Responses to <i>Mycobacterium tuberculosis</i> Associate with Resistance to Tuberculin Skin Test and Interferon Gamma Release Assay Conversion. <i>MSphere</i> , 2022, 7, .	1.3	8
165	Performance of verbal autopsy methods in estimating HIV-associated mortality among adults in South Africa. <i>BMJ Global Health</i> , 2018, 3, e000833.	2.0	7
166	Meta-analysis of HIV-1 vaccine elicited mucosal antibodies in humans. <i>Npj Vaccines</i> , 2021, 6, 56.	2.9	7
167	Seroprevalence of <i>Aspergillus</i> -Specific IgG Antibody among Mozambican Tuberculosis Patients. <i>Journal of Fungi (Basel, Switzerland)</i> , 2021, 7, 595.	1.5	7
168	Brief Report. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 70, 104-108.	0.9	6
169	Adaptation of WHO's generic tuberculosis patient cost instrument for a longitudinal study in Africa. <i>Global Health Action</i> , 2021, 14, 1865625.	0.7	6
170	Eligibility for Isoniazid Preventive Therapy in South African Gold Mines. <i>PLoS ONE</i> , 2013, 8, e81376.	1.1	6
171	The HVTN503/Phambili HIV vaccine trial: a comparison of younger and older participants. <i>International Journal of STD and AIDS</i> , 2014, 25, 332-340.	0.5	5
172	Uptake of Genital Mucosal Sampling in HVTN 097, a Phase 1b HIV Vaccine Trial in South Africa. <i>PLoS ONE</i> , 2014, 9, e112303.	1.1	5
173	Household point of care CD4 testing and isoniazid preventive therapy initiation in a household TB contact tracing programme in two districts of South Africa. <i>PLoS ONE</i> , 2018, 13, e0192089.	1.1	5
174	Tuberculosis active case finding: uptake and diagnostic yield among minibus drivers in urban South Africa. <i>BMC Public Health</i> , 2015, 15, 242.	1.2	4
175	Linkage to care among adults being investigated for tuberculosis in South Africa: pilot study of a case manager intervention. <i>BMJ Open</i> , 2018, 8, e021111.	0.8	4
176	Cost-effectiveness of a 12 country intervention to scale up short course TB preventive therapy among people living with HIV. <i>Journal of the International AIDS Society</i> , 2020, 23, e25629.	1.2	4
177	Strengthening health systems to improve the value of tuberculosis diagnostics in South Africa: A cost and cost-effectiveness analysis. <i>PLoS ONE</i> , 2021, 16, e0251547.	1.1	4
178	Effect of HIV Envelope Vaccination on the Subsequent Antibody Response to HIV Infection. <i>MSphere</i> , 2020, 5, .	1.3	3
179	Causes and Outcomes of Admission and Investigation of Tuberculosis in Adults with Advanced HIV in South African Hospitals: Data from the TB Fast Track Trial. <i>American Journal of Tropical Medicine and Hygiene</i> , 2021, , .	0.6	3
180	Sub-Lineage Specific Phenolic Glycolipid Patterns in the <i>Mycobacterium tuberculosis</i> Complex Lineage 1. <i>Frontiers in Microbiology</i> , 2022, 13, 832054.	1.5	3

#	ARTICLE	IF	CITATIONS
181	Opportunities afforded by new drugs for tuberculosis. <i>Lancet Infectious Diseases</i> , The, 2010, 10, 368-369.	4.6	2
182	Tuberculosis: The global killer. <i>South African Journal of Science</i> , 2013, 109, 2.	0.3	2
183	The effect of host factors on discriminatory performance of a transcriptomic signature of tuberculosis risk. <i>EBioMedicine</i> , 2022, 77, 103886.	2.7	2
184	<i>Mycobacterium tuberculosis</i> infection, immune activation, and risk of HIV acquisition. <i>PLoS ONE</i> , 2022, 17, e0267729.	1.1	2
185	Health-related quality of life and psychological distress among adults in Tanzania: a cross-sectional study. <i>Archives of Public Health</i> , 2022, 80, .	1.0	1
186	Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa: authors' reply. <i>Aids</i> , 2009, 23, 872-873.	1.0	0
187	Tuberculosis and HIV. , 0, , 457-478.		0
188	Improved services to enrollees into an HIV rural care and treatment center in Tanzania. <i>Pan African Medical Journal</i> , 2013, 16, 34.	0.3	0
189	Regarding the effect of cured tuberculosis disease on longevity. <i>International Journal of Tuberculosis and Lung Disease</i> , 2015, 19, 367-367.	0.6	0
190	Title is missing!. , 2020, 15, e0243707.		0
191	Title is missing!. , 2020, 15, e0243707.		0
192	Title is missing!. , 2020, 15, e0243707.		0
193	Title is missing!. , 2020, 15, e0243707.		0